DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for mucopolysaccharidosis type 3B — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMucopolysaccharidosis type 3B maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mucopolysaccharidosis type 3b is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
N-acetyl-alpha-glucosaminidase (NAGLU) — NAGLU is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet xyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4XWH · 2.32 Å · ligand Xylitol (XYL). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts provided are about mucopolysaccharidosis types I and II, not type 3B. No data on mucopolysaccharidosis type 3B appear in these texts. One abstract reports that enzyme replacement therapy for MPS I cannot cross the blood-brain barrier, and that haematopoietic stem cell transplantation carries higher risk but can preserve central nervous system function. Another describes a case of MPS II in an eight-year-old diagnosed five years after onset, with severe cardiovascular complications and a urinary MPS level of 69.6 mg/mmol (normal 0.0–11.6 mg/mmol). The authors note that scarce availability and high cost of diagnostic tests are constraints in resource-limited countries.
A third abstract states that for MPS I, the earlier the disease is detected, the better and more effective the treatment, which may be enzyme replacement therapy or haematopoietic stem cell transplantation. A fourth abstract provides general management guidelines for MPS I, recommending comprehensive baseline evaluations and monitoring every 6 to 12 months, with treatment consisting of palliative care, stem cell transplantation, or enzyme replacement therapy. None of these documents address MPS 3B specifically.
What is missing for mucopolysaccharidosis type 3B is any abstract that studies that disease. There is no evidence here on whether any existing drug, including those used for other MPS types, has been tested in MPS 3B. No clinical trial data, no survival or response rates, and no patient stratification for MPS 3B are provided. Without dedicated funding and a trial designed specifically for MPS 3B, no conclusions can be drawn.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PEDIATRICS · 2008 · 460 citations
Mucopolysaccharidosis I: Management and Treatment Guidelines
AbstractOBJECTIVE: Disease management for mucopolysaccharidosis type I has been inconsistent because of disease rarity (approximately 1 case per 100,000 live births), phenotypic heterogeneity, and limited therapeutic options. The availability of hematopoietic stem cell transplantation and the recent introduction of enzyme replacement therapy for mucopolysaccharidosis I necessitate the establishment of system-specific management guidelines for this condition. METHODS: Twelve international experts on mucopolysaccharidosis I met in January 2003 to draft management and treatment guidelines for mucopolysaccharidosis I. Initial guidelines were revised and updated in 2008, on the basis of additional clinical data and therapeutic advances. Recommendations are based on our extensive clinical experience and a review of the literature. RESULTS: All patients with mucopolysaccharidosis I should receive a comprehensive baseline evaluation, including neurologic, ophthalmologic, auditory, cardiac, respiratory, gastrointestinal, and musculoskeletal assessments, and should be monitored every 6 to 12 months with individualized specialty assessments, to monitor disease progression and effects of intervention. Patients are best treated by a multidisciplinary team. Treatments consist of palliative/supportive care, hematopoietic stem cell transplantation, and enzyme replacement therapy. The patient's age (>2 years or < or =2 years), predicted phenotype, and developmental quotient help define the risk/benefit profile for hematopoietic stem cell transplantation (higher risk but can preserve central nervous system function) versus enzyme replacement therapy (low risk but cannot cross the blood-brain barrier). CONCLUSION: We anticipate that provision of a standard of care for the treatment of patients with mucopolysaccharidosis I will optimize clinical outcomes and patients' quality of life.
Ethiopian Journal of Health Sciences · 2015 · 5 citations · open access
Challenges in the Management of Mucopolysaccharidosis Type II (Hunter’s Syndrome) in a Developing Country: a Case Report
AbstractBACKGROUND: Mucopolysaccharidosis type II (Hunter's syndrome) is an X-linked chromosomal storage disorder due to deficiency of the lysosomal enzyme iduronate-2-sulfatase with patients rarely living till adulthood. Failure to identify patients early could contribute to an increased morbidity as identified in this case report. CASE DETAILS: An eight year old patient with Hunter's syndrome identified five years after disease onset with severe cardiovascular complications exemplifies the challenges faced in resource-limited countries towards making diagnosis and treatment of rare conditions. Elevated urinary glycosaminoglycans levels or a strong clinical suspicion of Hunter's syndrome, as identified in the index case, is a prerequisite for enzyme activity testing. Urinary mucopolysaccharide(MPS) level was 69.6 mg/mmol(normal range is 0.0 - 11.6 mg/mmol), and the confirming MPS electrophoresis analysis showed elevated heparan sulphate in the urine sample. Enzyme activity testing, with absent or very low iduronate-2-sulfatase activity, is diagnostic. However, the scarce availability and high cost of these tests is another constraint in making a diagnosis. CONCLUSION: Identification and management of mucopolysaccharidosis type II pose a problem in resource-constrained countries due to late presentation, lack of facility for diagnosis and treatment, cost and expertise required for the management.
Педиатрическая фармакология · 2022 · 2 citations · open access
Modern Approaches to the Management of Children with Mucopolysaccharidosis Type I
AbstractThis article presents modern data on epidemiology, etiology, and clinical manifestations of mucopolysaccharidosis (MPS) type I in children. MPS develops due to deficiency of particular lysosomal enzyme which determines the disease type. The article considers in details disease's pathogenesis and classification. Evidence-based approaches to diagnosis (differential diagnosis included) are covered, moreover, special attention is paid to pathogenetic, symptomatic, and surgical treatment of MPS.
Residência Pediátrica · 2021 · 0 citations · open access
Hurler syndrome: diagnostic journey in an orphan disease - case report
AbstractOBJECTIVES: Promote the early detection of the disease through pertinent clinical findings in patients with mucopolysaccharidosis. CASE REPORT: Patient with MPS I with typical clinical signs of the disease from a very early age were diagnosed only at 22 months old and will begin enzymatic replacement therapy. DISCUSSION: The disease, the earlier it is detected, the better and more effective the treatment, which may be enzyme replacement therapy, or, in the last case, transplantation of hematopoietic stem cells.
Arquivos de Neuro-Psiquiatria · 2023 · 0 citations · open access
Mucopolysaccharidosis III at the reference center for rare diseases of Ceará
AbstractBackground: Mucopolysaccharidosis type III (MPS III) is the type of mucopolysaccharidosis that has fewer systemic signs and symptoms, however, it has the most severe neurological impairment. There are four types of MPS III, determined by the mutation in the gene responsible for the enzyme that becomes deficient in degrading intracellular glycosaminoglycan, which is responsible for the clinical picture.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
